"Teniposide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.
Below are MeSH descriptors whose meaning is more general than "Teniposide".
Below are MeSH descriptors whose meaning is more specific than "Teniposide".
This graph shows the total number of publications written about "Teniposide" by people in this website by year, and whether "Teniposide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Teniposide" by people in Profiles.
t(3;11) translocation in treatment-related acute myeloid leukemia fuses MLL with the GMPS (GUANOSINE 5' MONOPHOSPHATE SYNTHETASE) gene. Blood. 2000 Dec 15; 96(13):4360-2.
Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood. 1996 Mar 01; 87(5):1912-22.
The effect of topoisomerase inhibitors on the expression of differentiation markers and cell cycle progression in human K-562 leukemia cells. Exp Cell Res. 1992 Nov; 203(1):100-6.
Phase II trial of teniposide in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial. Cancer Treat Rep. 1986 Feb; 70(2):307-8.
High-dose Ara-C plus VM-26 in adult acute lymphoblastic leukemia. Eur J Cancer Clin Oncol. 1985 Oct; 21(10):1261-3.
Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study. Cancer Treat Rep. 1982 Feb; 66(2):405-6.
Treatment of grade III and IV astrocytomas with BCNU alone and in combination with VM-26 following surgery and radiation therapy. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):1707-11.